Cidara Therapeutics Stock Forward View - Relative Strength Index
| CDTXDelisted Stock | USD 221.38 0.06 0.03% |
Cidara Therapeutics's Relative Strength Index forecast reference data is generated from the equity's historical trading prices. This page presents the model output and associated accuracy measures as reference information.
The Relative Strength Index projections for Cidara Therapeutics are reference data based on historical daily prices and are provided as informational context. Relative Strength Index Analysis Today
Cidara Therapeutics has current Relative Strength Index of 77.4.| Volatility | Backtest | Information Ratio |
Cidara Therapeutics Trading Date Momentum
| On March 22 2026 Cidara Therapeutics was traded for 221.38 at the closing time. The top price for the day was 221.41 and the lowest listed price was 221.25 . There was no trading activity during the period. Lack of trading volume on March 22, 2026 did not affect price variability. The overall trading delta against the current closing price is -0.03% . |
Compare Cidara Therapeutics to competition
Cidara Therapeutics Related Equities
The following equities are related to Cidara Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Cidara Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Cidara Therapeutics Market Strength Events
Understanding the market strength of Cidara Therapeutics stock enables investors to assess the security's momentum and responsiveness to broader market forces. These indicators are essential tools for timing trades in Cidara Therapeutics with greater precision.
Cidara Therapeutics Risk Indicators
Reviewing Cidara Therapeutics' basic risk indicators is essential for investors who want to forecast its price and manage their investment risk effectively. This analysis helps identify the amount of risk involved in holding Cidara Therapeutics' and informs decisions about hedging and position.
| Mean Deviation | 4.25 | |||
| Semi Deviation | 1.3 | |||
| Standard Deviation | 13.28 | |||
| Variance | 176.3 | |||
| Downside Variance | 6.8 | |||
| Semi Variance | 1.7 | |||
| Expected Short fall | -4.61 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Cidara Therapeutics
The amount of media and story coverage tied to Cidara Therapeutics can signal where market attention is concentrating at the moment. The practical risk is that faster visibility can increase both interest and skepticism at the same time.
Contributor Headline
Latest Perspective From Macroaxis
Cidara Therapeutics Short Properties
Reviewing short-oriented indicators for Cidara Therapeutics is useful because long and short participants often create very different signals for timing and volatility. This is most valuable when investors want to know whether bearish pressure is starting to shape the market's reaction function.
| Common Stock Shares Outstanding | 6.3 M | |
| Cash And Short Term Investments | 189.8 M |
Cidara Therapeutics has a market cap of 6.96 B, ROE of -68.7%. Use Trending Equities to view allocation positioning. Current allocation data is available for review. The summary draws on available position and value data. This view summarizes available data without implying outcomes. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. Cidara Therapeutics currently shows ROE of -68.7%, market cap of 6.96 Billion. Cidara Therapeutics analysis should be paired with portfolio risk and diversification tools before adjusting allocations. For Cidara Therapeutics, the analytical tools below add portfolio-level context that single-security review alone cannot provide. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Cidara Stock
Cidara Therapeutics historical volatility may reflect structural changes following delisting.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |